Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956094 | 1.00 | HTT (0.36) | HTTHSD17B10HDAC6ELANEKDM4E | |
| SCHEMBL27194760 | 0.86 | GRM4 (0.33) | KDM4ESSTR4GAA | |
| SCHEMBL15533151 | 0.78 | SSTR4 (0.32) | HCRTR1HCRTR2SSTR4 | |
| SCHEMBL25707523 | 0.74 | HTT (0.35) | HTTHSD17B10MGLL | |
| SCHEMBL30050607 | 0.74 | HTT (0.35) | HTTHSD17B10MGLL | |
| SCHEMBL29955831 | 0.74 | HTT (0.35) | HTTHSD17B10MGLL | |
| SCHEMBL29952041 | 0.74 | HTT (0.35) | HTTHSD17B10MGLL | |
| SCHEMBL29951895 | 0.73 | HTT (0.41) | HTTHSD17B10MGLL | |
| SCHEMBL5128448 | 0.73 | SSTR4 (0.37) | SSTR4DHODH | |
| SCHEMBL12097746 | 0.73 | SCN9A (0.41) | HCRTR1HCRTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116891-A1 | Oxazepin Derivative | TEIJIN PHARMA LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| EP-4512811-A1 | OXAZEPINE DERIVATIVE | Teijin Pharma Limited (JP) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023122093-A1 | REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4182313-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-111094271-B | Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds | 思普瑞特生物科学公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-4055013-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-109311887-B | Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions | BIAL研发投资股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | HTT 3216/4885HSD17B10 1103/4885HDAC6 647/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | HTT 3216/4885HSD17B10 1103/4885HDAC6 647/4885 |
| US-20260116891-A1 | Oxazepin Derivative | HCRTR2, HCRTR1, OXTR | HTT 1846/4885HSD17B10 751/4885HDAC6 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.